Forum on Neuroscience and Nervous System Disorders 2012 Annual Report (2013) / Chapter Skim
Currently Skimming:
Forum on Neuroscience and Nervous System Disorders: 2012 Annual Report
Forum on Neuroscience and Nervous System Disorders: 2012 Annual Report
Pages 1-12
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
BOARD ON HEALTH SCIENCES POLICY Forum on Neuroscience and Nervous System Disorders 2012 Annual Report
|
From page 2... ...
Cover Image Credits Left: Greg Hood, John Burkardt, and Greg Foss, Pittsburgh Supercomputing Center Right: Paul Thompson and Arthur Toga, UCLA
|
From page 3... ...
Looking ahead to 2013, the Forum plans an array of activities on topics such as: • Accelerating therapeutic development for nervous system disorders towards first-in-human trials • Improving access to essential medicines for mental, neurological and substance use disorders in sub-Saharan Africa • Data standards to enable analysis of large basic research datasets • Defining the precompetitive space in neuroscience • Clinical trials infrastructure • Gene therapy and stem cell transplantation for the eye and brain I look forward to another productive year for the Forum. Steve Hyman Chair
|
From page 4... ...
Yet, a large gap remains in treatment options that are high in efficacy, but low in side effects, for many diseases. Given the tremendous disease burden associated with nervous system diseases and disorders, the Forum hosted a workshop that brought key stakeholders together to discuss potential opportunities for maximizing the translation of effective therapies from animal models to clinical practice.
|
From page 5... ...
In addition, participants discussed potential mechanisms for task shifting and task sharing within human resources and across treatment locations. Sharing Clinical Research Data Pharmaceutical companies, academic institutions, advocacy organizations, and government agencies such as the Food and Drug Administration and the National Institutes of Health have large quantities of clinical research data.
|
From page 6... ...
During the workshop, models and projects that involve sharing other types of data were highlighted to the extent that these models provide lessons and best practices applicable to sharing preplanned interventional clinical research data. Jun 25 Molecules to Mind: Oct 15–16 Grand Challenges Workshop 7th meeting 2008 2009 2008 Jan 30 Jun 24 Oct 3 2 5th meeting 6th meeting Venture Philanthropy Strategies Workshop
|
From page 7... ...
In addition, the workshop will examine regulatory mechanisms that may facilitate faster entry of potential treatments into first-in-human trails and identify potential metrics for determining readiness for first-in-human trials. Improving Access to Essential Medicines for Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa Sub-Saharan Africa (SSA)
|
From page 8... ...
opportunities for providing access to essential medicines for MNS disorders. Specifically, participants will examine successful models in a variety of disease areas and in low- and middle-income countries outside of SSA.
|
From page 9... ...
A working group will be established to examine current practices of training scientists and identify opportunities for increasing and strengthening translational neuroscience programs. Mental Health, Neurological, and Substance Use Disorders in Sub-Saharan Africa In collaboration with the World Health Organization mental health Gap Action Programme (mhGAP)
|
From page 10... ...
Health System National Institute on Alcohol Abuse C Thomas Caskey Story Landis and Alcoholism Baylor College of Medicine National Institute of Neurological John Williams Timothy Coetzee Disorders and Stroke Wellcome Trust FastForward of the National Alan Leshner Stevin Zorn Multiple Sclerosis Society American Association for the Lundbeck USA Emmeline Edwards Advancement of Science Charles Zorumski National Center for Complementary Husseini Manji Washington University School of Medicine and Alternative Medicine Johnson & Johnson Pharmaceuticals Martha Farah David Michelson University of Pennsylvania Merck Research Laboratories Richard Frank Richard Mohs IOM Staff Bruce Altevogt, Ph.D.
|
From page 11... ...
Alzheimer's Association Nonprofit CeNeRx Biopharma Department of Veterans Affairs Eli Lilly and Company 10% Foundation for the National Institutes of Health GE Healthcare GlaxoSmithKline Federal Johnson & Johnson Pharmaceuticals 47% Lundbeck USA 43% Merck Research Laboratories Industry The Michael J Fox Foundation for Parkinson's Research National Eye Institute National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute on Drug Abuse National Institutes of Health Blueprint for Neuroscience Research National Multiple Sclerosis Society National Science Foundation One Mind for Research Pfizer, Global Research and Development Society for Neuroscience Wellcome Trust Apr 8–9 Accelerating Therapeutic Oct 8 Development Workshop 20th meeting
|
From page 12... ...
The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.